Spoken Alpha
Enveric Biosciences, Inc.
Enveric Biosciences develops small-molecule neuroplastogenic therapeutics designed to treat psychiatric and neurological disorders. The company advances a pipeline of novel psychedelic-inspired compounds, including its lead candidate EB-003, which targets depression and anxiety without hallucinogenic effects.
Enveric Biosciences, Inc is a Healthcare company operating in Biotechnology with a $6.4M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 13, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add ENVB, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ENVB.
$ curl https://api.spokenalpha.com/v1/companies/ENVBFAQ
Spoken Alpha indexes ENVB's earnings call transcripts at https://spokenalpha.com/companies/ENVB. Each call links to attributed speakers and parsed analyst Q&A. Enveric Biosciences, Inc.'s own investor relations page is at https://www.enveric.com/investors/.
Enveric Biosciences, Inc. (ENVB) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | $-0.76 | — | — | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-18 | $-1.08 | — | — | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-3.81 | — | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-10.81 | $-0.35 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-11.65 | $-0.35 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-4.82 | $-0.40 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-27 | $-2.03 | $-2.76 | +26.5% | $340.4K | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-43.20 | $-93.60 | +53.8% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-45.00 | $-99.00 | +54.5% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-109.80 | $-139.50 | +21.3% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-25 | $-1.47 | $-1.54 | +4.5% | $647.1K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-287.12 | $-376.20 | +23.7% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-450.42 | $-117.00 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-4.24 | $-2.23 | -89.9% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-344.11 | $-525.60 | +34.5% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-582.21 | $-720.00 | +19.1% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-818.08 | $-675.00 | -21.2% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-990.00 | $-1080.00 | +8.3% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-89.00 | $-8.00 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-1080.00 | $-1260.00 | +14.3% | $0 | — | — | EODHD |
Source: EODHD. ENVB reported actuals as published; sparse fields render as —.